Semaglutide to prevent weight gain after liver transplant
Treatments studied
Part of Digestive system clinical trials.
This trial tests semaglutide (a diabetes/weight-loss medicine) to help prevent weight gain after liver transplant. It is also looking at blood sugar and safety while you continue your transplant medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–75 and had a liver transplant 8–24 weeks ago
- You are eating normally after discharge and can consent to the study
- You have higher-than-normal blood sugar (diabetes or pre-diabetes based on labs or meds)
- Your transplanted liver is working normally and your anti-rejection medicines are stable
- Your body weight is higher than the trial’s cutoff (BMI above 27)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two diabetes medicines—semaglutide and sitagliptin—in people who have had a liver transplant and have type 2 diabetes (or diabetes after transplant). It’s looking to see which medicine works better and is safe for blood sugar control in the transplant setting.
This Phase 2 study tests how semaglutide (a diabetes medication also used for weight) affects fatty liver and the liver’s response to sugar. It may help people with non-alcoholic fatty liver disease understand whether the drug improves liver fat and related changes.
This study tests if an oral semaglutide pill can reduce liver fat and improve body composition in people who have had a liver transplant and have diabetes. It may help manage weight and blood sugar after transplant.
This trial tests if the drug semaglutide can prevent the development of diabetes in people who have recently had a kidney transplant. It may help those at higher risk for post-transplant diabetes.
This trial tests semaglutide, a medicine that helps lower blood sugar, in people who develop high blood sugar shortly after a kidney transplant. It may help control blood sugar without harming the transplanted kidney, while also checking safety in this specific group.
This study looks at whether the oral medication semaglutide can help treat chronic kidney disease in people who have both type 2 diabetes and a fatty liver related to metabolism. It aims to see if the drug can improve kidney function and liver health.
Hear when a new NAFLD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.